Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells

International Journal of Hematology

Volumn 96, Issue 5, 2012, Pages 649-656

  Cruet Hennequart, Séverine ^a,b   Prendergast, Áine M ^a   Shaw, Georgina ^a   Barry, Frank P ^a   Carty, Michael P ^a,c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITÉ DE CAEN   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell cycle arrest; DNA damage response; Doxorubicin; Genome integrity; Leukemia; Mesenchymal stem cells; Phosphorylation

Indexed keywords

CASPASE 3; CHECKPOINT KINASE 1; DOXORUBICIN; HISTONE H2AX;

APOPTOSIS; ARTICLE; CANCER PATIENT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DRUG RESPONSE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DNA DAMAGE; DOXORUBICIN; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONES; HUMANS; INORGANIC PYROPHOSPHATASE; K562 CELLS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MESENCHYMAL STROMAL CELLS; MITOCHONDRIAL PROTEINS; PHOSPHORYLATION; PROTEIN KINASES;

EID: 84872189518     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1196-5     Document Type: Article

References (39)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-4.
2. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol. 1999;181:67-73.
3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7.
4. Zhu J, Emerson SG. A new bone to pick: osteoblasts and the haematopoietic stem-cell niche. BioEssays. 2004;26:595-9.
5. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev. 2009;18:1247-52.
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56:185-229.
7. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006;66:4863-71.
8. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433-9.
9. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739-45.
10. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol. 2001;13:225-31.
11. Devine SM, Hoffman R. Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol. 2000;7:358-63.
12. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008; 26:2287-99.
13. Wang T, Xu Z, Jiang W, Ma A. Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell. Int J Cardiol. 2006;109:74-81.
14. Prendergast AM, Cruet-Hennequart S, Shaw G, Barry FP, Carty MP. Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or gamma-irradiation. Cell Cycle. 2011;10(21):3768-77.
15. Cruet-Hennequart S, Prendergast AM, Barry FP, Carty MP. Human mesenchymal stem cells (hMSCs) as targets of DNA damaging agents in cancer therapy. Curr Cancer Drug Targets. 2010;10:411-21.
16. Cruet-Hennequart S, Villalan S, Kaczmarczyk A, O'Meara E, Sokol AM, Carty MP. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle. 2009;8:3039-50.
17. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724-37.
18. Yoshida K, Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010;101:831-5.
19. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16:376-83.
20. Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells. 2006;24:2753-65.
21. Wang D, Jang DJ. Protein kinase CK2 regulates cytoskeletal reorganization during ionizing radiation-induced senescence of human mesenchymal stem cells. Cancer Res. 2009;69:8200-7.
22. Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res. 1993;17:1045-50.
23. Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene. 2003;22:5834-47.
24. Matsuura K, Wakasugi M, Yamashita K, Matsunaga T. Cleavagemediated Activation of Chk1 during Apoptosis. J Biol Chem. 2008;283:25485-91.
25. Leung-Pineda V, Huh J, Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 2009;69:2630-7.
26. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 2005;19:607-18.
27. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin Activates ATM-dependent Phosphorylation of Multiple Downstream Targets in Part through the Generation of Reactive Oxygen Species. J Biol Chem. 2004;279:53272-81.
28. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858-68.
29. Oakley GG, Patrick SM. Replication protein A: directing traffic at the intersection of replication and repair. Front Biosci. 2010;15: 883-900.
30. Kim HS, Lee YS, Kim DK. Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology. 2009;84:300-9.
31. Jager M, Schultheis A, Westhoff B, Krauspe R. Osteogenic progenitor cell potency after high-dose chemotherapy (COSS- 96). Anticancer Res. 2005;25:947-54.
32. de Lima Prata K, Orellana MD, De Santis GC, Kashima S, Fontes AM, de Cássia Viu Carrara R et al. Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp Hematol. 2010;38: 292-300.e4.
33. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007;117:3248-57.
34. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431: 997-1002.
35. Rossi DJ, Seita J, Czechowicz A, Bhattacharya D, Bryder D, Weissman IL. Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. Cell Cycle. 2007;6:2371-6.
36. Barta T, Vinarsky V, Holubcova Z, Dolezalova D, Verner J, Pospisilova S, et al. Human embryonic stem cells are capable of executing G1/S checkpoint activation. Stem Cells. 2010;28: 1143-52.
37. Momcilovic O, Choi S, Varum S, Bakkenist C, Schatten G, Navara C. Ionizing radiation induces ataxia telangiectasia mutated- dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells. 2009;27:1822-35.
38. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257-72.
39. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011;20:370-83.